HiLung Inc. is honored to announce that we have been selected to present at Innovation Tiger, a premier platform that highlights high-potential companies with disruptive technologies and business models. The event will be held on September 30 at Shonan iPark.

Our proprietary human iPSC-derived lung organoid technology is gaining significant recognition worldwide as a transformative platform for elucidating the mechanisms of lung disease, accelerating drug discovery, and advancing pulmonary toxicity testing—not only for pharmaceuticals but also for environmental toxicants. This selection underscores the unique value proposition and societal impact of HiLung’s innovation.

Presenting at Innovation Tiger provides us with an exceptional opportunity to showcase our technological strengths, commercialization strategy, and growth potential to a broad audience of investors, industry leaders, and policymakers. We remain committed to driving the next generation of medical and drug discovery innovation through strong collaboration across academia, industry, and government.

We sincerely thank our stakeholders for their continued trust and support, and we look forward to sharing more about HiLung’s progress and future vision at Shonan iPark on September 30.

【Press Release】ピッチイベント「イノベーションタイガー2025」日韓台選抜16組が決定 現役大手製薬企業/VC総勢８社の豪華審査員が鋭く迫ります | ニュース | 湘南ヘルスイノベーションパーク (湘南アイパーク)